Heather Raymon
Förmögenhet: 1 M $ per 2026-05-31
Förmögenhet: 1 M $ per 2026-05-31
Heather Raymon currently works at Artiva Biotherapeutics, Inc., as Senior VP-Research & Early Development from 2023.
Dr. Raymon also formerly worked at Bristol Myers Squibb Co., as Executive Director-Early Development Program and Celgene Corp., as Senior Director & Head-Pharmacology.
Dr. Raymon received her undergraduate degree from State University of New York at Albany and doctorate degree from the University of California, Irvine.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-05-19 | 148 228 ( 0,31 % ) | 1 M $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Företagsledare/Principal | 2020-10-01 |
| Företag | Position | Slut |
|---|---|---|
| CELGENE | Företagsledare/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Företagsledare/Principal | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
State University of New York at Albany
State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån